Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov 1;15(6):718-723.
doi: 10.1097/ICB.0000000000000876.

UVEITIS CAUSED BY TREATMENT FOR MALIGNANT MELANOMA: A CASE SERIES

Eline Whist  1 , Richard J Symes  1   2 , John H Chang  3   4 , Vivek Chowdhury  5 , Li-Anne Lim  1 , John R Grigg  1   2 , Ming-Lee Lin  6 , Tanya Karaconji  1 , Michael Giblin  1 , Andrew Symons  7 , Lyndell L Lim  6   7   8 , Peter J McCluskey  1   2
Affiliations
Case Reports

UVEITIS CAUSED BY TREATMENT FOR MALIGNANT MELANOMA: A CASE SERIES

Eline Whist et al. Retin Cases Brief Rep. .

Abstract

Background/purpose: To report the largest case series to date of uveitis occurring in association with immunomodulatory therapy for malignant melanoma.

Methods: A retrospective multicenter case review. Twenty-two patients with uveitis occurring in association with either immunotherapy or targeted immune therapy for malignant melanoma were identified.

Results: Of 22 patients, 11 had anterior uveitis in isolation. The remainder showed a variety of clinical features including panuveitis, ocular hypotony, papillitis, cystoid macular edema, and melanoma-associated retinopathy. Most patients responded well to treatment.

Conclusion: We report the largest case series to date of patients with uveitis secondary to drug treatment for malignant melanoma. These cases are likely to increase in number in the future as newer immunomodulatory therapies for cancers are developed and the indications for these drugs increase. A dilemma arises when patients respond well to these drugs but develop vision-threatening side effects.

PubMed Disclaimer

Conflict of interest statement

None of the authors has any financial/conflicting interests to disclose.

Figures

Fig. 1.
Fig. 1.
The left eye of Case 1 showing vitreous haze. There are underlying choroidal effusions.
Fig. 2.
Fig. 2.
Color images, fundus autofluorescence, optical coherence tomography, and electrophysiology for Case 2. A. Color fundus photographs of both eyes (B) autofluorescence of both eyes (C) optical coherence tomography of the right eye, and (D) optical coherence tomography of the left eye, both showing cystoid macular changes.
See this image and copyright information in PMC

References

    1. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015;161:205–214. - PMC - PubMed
    1. Kim T, Amaria RN, Spencer C, et al. . Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014;11:237–246. - PMC - PubMed
    1. Choe CH, McArthur GA, Caro I, et al. . Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 2014;158:831–837. - PubMed
    1. Della Vittoria Scarpati G, Fusciello C, Perri F, et al. . Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 2014;7:203–209. - PMC - PubMed
    1. Thomas M, Armenti ST, Ayres MB, Demirci H. Uveal effusion after immune checkpoint Inhibitor therapy. JAMA Ophthalmol 2018;136:553–556. - PMC - PubMed